← Back to Clinical Trials
Recruiting NCT01177618

NCT01177618 Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01177618
Status Recruiting
Phase
Sponsor Brigham and Women's Hospital
Condition Chronic Obstructive Pulmonary Disease
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 1994-07
Primary Completion 2027-07

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 1994-07 with a primary completion date of 2027-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic obstructive pulmonary disease (COPD) is often caused by cigarette smoking, but genetic predisposition also influences COPD susceptibility. The purpose of this study is to identify genetic factors that predispose some individuals to develop COPD.

Eligibility Criteria

Inclusion Criteria for Early-Onset COPD Probands: * Early onset of COPD in individuals younger than 53 years old * Spirometry results that are indicative of severe COPD (FEV1 \< 40% predicted) * Physician-diagnosed COPD Exclusion Criteria for Early-Onset COPD Probands: * Severe alpha-1 antitrypsin deficiency * Other chronic lung diseases in participants with COPD (except asthma) * Pregnant * Any previous lung surgery including lung transplant or lung reduction volume surgery (LVRS); unless prior Pulmonary Function Tests are available

Contact & Investigator

Central Contact

Edwin K. Silverman, M.D., Ph.D.

✉ ed.silverman@channing.harvard.edu

📞 617-525-2128

Principal Investigator

Edwin K. Silverman, M.D., Ph.D.

PRINCIPAL INVESTIGATOR

Brigham and Women's Hospital

Frequently Asked Questions

Who can join the NCT01177618 clinical trial?

This trial is open to participants of all sexes, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01177618 currently recruiting?

Yes, NCT01177618 is actively recruiting participants. Contact the research team at ed.silverman@channing.harvard.edu for enrollment information.

Where is the NCT01177618 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT01177618 clinical trial?

NCT01177618 is sponsored by Brigham and Women's Hospital. The principal investigator is Edwin K. Silverman, M.D., Ph.D. at Brigham and Women's Hospital. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology